Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin

• Published in: Muscle & nerve Vol. 18; no. 7; p. 720
• Main Authors: Van den Bergh, P, Francart, J, Mourin, S, Kollmann, P, Laterre, E C
• Format: Journal Article
• Language: English
• Published: United States 01.07.1995
• Subjects: Adult; Aged; Blepharospasm - drug therapy; Botulinum Toxins - adverse effects; Botulinum Toxins - therapeutic use; Dose-Response Relationship, Drug; Dystonia - drug therapy; Female; Follow-Up Studies; Humans; Male; Meige Syndrome - drug therapy; Middle Aged; Movement Disorders - drug therapy; Movement Disorders - physiopathology; Muscle Cramp - drug therapy; Spasm - drug therapy; Time Factors; Videotape Recording
• ISSN: 0148-639X
• DOI: 10.1002/mus.880180708

We report the results of botulinum toxin type A (Dysport, Porton Products, UK) treatment over 5 years in 107 patients with blepharospasm, Meige's syndrome, oromandibular dystonia, hemifacial spasm, cervical dystonia, and writer's cramp. Electromyography was used to localize dystonic muscles and guide Dysport injections in Meige's syndrome, oromandibular dystonia, cervical dystonia, and writer's cramp. All but 2 Meige's syndrome and 2 writer's cramp patients responded to treatment. Improvement was dramatic in blepharospasm (79%) and hemifacial spasm (90%); pronounced in cervical dystonia (74%); and moderate in Meige's syndrome (53%), oromandibular dystonia (57%), and writer's cramp (34%). Although Dysport doses were 50-75% lower than usually reported, response and improvement rates as well as relapse intervals were similar to those of others. To treat cervical dystonia relapses, only 50% of the initial dose was required for continued optimal relief of symptoms. Low-dose Dysport was associated with a very low incidence of dysphagia in cervical dystonia.